Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis by April W. Armstrong, Andrew F. Alexis, Andrew Blauvelt, Jonathan I. Silverberg, Claire Feeney, Mark Levenberg, Gary Chan, Fan Zhang, Luke Fostvedt

Connect to this object online.

Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical tria... by Carsten Flohr, Michael J. Cork, Michael R. Ardern-Jones, Lawrence F. Eichenfield, Sébastien Barbarot, Claire Feeney, Ricardo Rojo, Irina Lazariciu, John Nesnas

Connect to this object online.

Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations by Melinda J. Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, Michael J. Cork, Lawrence F. Eichenfield, Eric L. Simpson, Athanasios Tsianakas, Urs Kerkmann, Claire Feeney, William Romero

Connect to this object online.

Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate‐to‐severe atopic dermatitis by Delphine Staumont‐Sallé, Sébastien Barbarot, Jean David Bouaziz, Chan Chan, Claire Clibborn, Aurélie Du‐Thanh, Claire Feeney, Alexandre Lejeune, Laurent Misery, Audrey Nosbaum, Julien Seneschal, Angèle Soria, Fan Zhang

Connect to this object online.

Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE by Melinda J. Gooderham, MSc, MD, FRCPC, Chia-Yu Chu, MD, PhD, Ricardo Rojo, MD, Hernan Valdez, MD, Pinaki Biswas, PhD, Michael C. Cameron, MD, Claire Feeney, MD, PhD, Gerardo A. Encinas, MD, MHS, Kathleen Peeples-Lamirande, PharmD, MPH, Joseph C. Cappelleri, PhD, Daniela E. Myers, MPH, Marco DiBonaventura, PhD

Connect to this object online.